Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to acquire Hangzhou Laihe Biotech Co., Ltd, a move that will grant its subsidiary full control over the latter. This strategic acquisition is set to create synergies, given Laihe Bio’s specialization in drug testing and infectious disease testing products, which primarily utilize colloidal gold immunodiagnostic technology.
The deal is expected to bolster Orient Gene’s point-of-care testing (POCT) business on the global stage, enabling in-depth research and development initiatives in the realm of artificial intelligence combined with healthcare, and enhancing the company’s manufacturing capabilities.- Flcube.com
